Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

SPA for phase III study of glufosfamide for metastatic pancreatic cancer

Sep. 15, 2004

Iressa studied in new head-to-head trial for NSCLC

Sep. 15, 2004

Oncomer converts solitary tumor into bloodless mass

Sep. 15, 2004

AustCancer acquires North American rights to RP-101

Sep. 15, 2004

New phase IIIb study of Tarceva in advanced NSCLC

Sep. 15, 2004

Novel HDAC inhibitors prepared and tested at Oxford GlycoSciences

Sep. 15, 2004

Bonefos accepted for priority review

Sep. 14, 2004

Assessment of survival of advanced NSCLC patients treated with gefitinib

Sep. 13, 2004

Insmed's rhIGFBP-3 enters phase I study

Sep. 13, 2004

Incyte patent covers novel antitumor agents targeting JNK signaling pathways

Sep. 13, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...